Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial

Overview of attention for article published in Frontiers in Pharmacology, October 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (51st percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter: 4 X users

Readers on

mendeley: 6 Mendeley

Summary X

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 6,275 followers.

RT @Sarcoma_papers: Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial https:…

31 Dec 2022

Reply Repost Favourite

RT @Sarcoma_papers: Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial https:…

30 Dec 2022

Reply Repost Favourite

RT @Sarcoma_papers: Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial https:…

30 Dec 2022

Reply Repost Favourite

New Research: Efficacy and safety of sintilimab plus doxorubicin in advanced soft tissue sarcoma: A single-arm, phase II trial https://t.co/0ReR4nYXN1 #pharmacology

06 Oct 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.